期刊文献+

乙型肝炎病毒对HepG2细胞表达TLR3的影响 被引量:2

Heptitis B virus influence the expression of toll like receptors 3 in hepG2 cells
下载PDF
导出
摘要 目的乙肝病毒全基因组体外扩增,构建质粒并测序,酶切后瞬时转染HepG2细胞,观察对HBV抗原分泌,病原识别受体Toll样受体3(TLR3)的表达及细胞增殖的影响。方法长片段PCR法扩增HBVDNA全长,构建pBlueScript-HBV质粒并转化宿主菌,摇菌后提取质粒经测序,用SapⅠ酶切,获得HBV3.2kb基因组,采用脂质体瞬时转染HepG2细胞株,IMX检测HBV所分泌抗原,台盼蓝计数检测细胞增殖活性,直接免疫荧光流式细胞术(FCM)检测表达TLR3的阳性细胞百分率,并与空白对照组对比。结果HBsAg和HBeAg的分泌随着转染HBVDNA量的增加而升高,除4μg和6μg组两组间比较的表面抗原外,差异均有显著性(P<0.05)。TLR3在转染后均有上调,除4μg与6μg组间比较外,各组间差异有显著性(P<0.05)。台盼蓝拒染法示细胞存活随转染剂量的升高而减少(P<0.05),但4μg和6μg两组间比较差异无显著意义(P>0.05)。而各转染剂量组HBsAg和e抗原的分泌及细胞的存活数均与TLR3的表达呈显著正相关(P<0.01)。结论本研究初步表明乙肝病毒可能直接引起HepG2细胞TLR3的上调,而且上调可能启动了细胞的凋亡或坏死机制,成为HBV损伤细胞的非免疫细胞介导机制。 Objective To investigate the expression of Toll -like receptor 3 (TLR3) in HepG2 cells after transfection with hepatitis B virus genonle secretion of HBV antigen and the proliferation of cells after infection with HBV. Methods The experiments included creating pBluScript - HBV plasmid, sequencing, transforming bacteria, extracting plasmid, and cutting with enzyme Sap I, obtaining 3.2 kb genome, and transfecting HepG2 cells with lipofectamine 2000, detection of HBsAg and HBeAg, counting living cells. Trapan blue staining and examintion tile expression of TLR3 by FCM. Results HBsAg and HBeAg expression increased significantly with the transfection dosage except the expression of HBsAg in the 4 μg and 6 μg groups. The intensity of TLR3 expression in HepG2 cells was significantly higher than that of control group ( P 〈 0.05 ). The number of living cells was reduced with increasing transfection dosage. The expression of HBsAg and HBeAg and the number of living cells were positively correlated with intensity of TLR3. Conclusion HBV may result in TLR3 expression directly. It may result in cell apoptosis or necrosis directly via a non - immune mechanism.
出处 《广东医学》 CAS CSCD 北大核心 2007年第12期1905-1907,共3页 Guangdong Medical Journal
基金 教育部新世纪优秀人才支持计划(编号:NCET-04-0797) 广东省肝脏疾病研究重点实验室启动项目(编号:2005B60148)
关键词 乙型肝炎病毒 TOLL样受体3 HEPG2细胞株 Hepatitis B virus TLR3 HepG2 cell
  • 相关文献

参考文献10

  • 1VISVANATHAN K, SKINNER N A, THOMPSON A J, et al. Regulation of Toll - Like Receptor - 2 Expression in Chronic Hepatitis B by the Precore Protein[ J]. Hepatology, 2007, 45 ( 1 ) : 102 - 110. 被引量:1
  • 2阳凯,王琛.宿主细胞应答病毒感染的细胞信号转导研究新进展[J].生物化学与生物物理进展,2006,33(12):1138-1145. 被引量:8
  • 3卢建溪,谢冬英,徐启桓,朱明芬,陈伟,李莉,李刚.阿德福韦治疗过程中乙型肝炎病毒核酸序列的变化[J].中华肝脏病杂志,2006,14(5):331-336. 被引量:7
  • 4AKIRA S, TAKEDA K.Toll-like receptor signaling[ J]. Nat Rev Immunol, 2004, 4(7) : 499 -511. 被引量:1
  • 5MATSUMOTO M, FUNAML K, TANABE M, et al. Subeellular localization of Toll -like receptor 3 in human dendritic cells[ J ]. J Immunol, 2003, 171(6) : 3154 -3162. 被引量:1
  • 6MATSUM OTO M, KIKKAWA S, KOHASE M, et al. Establishment of a monoc lonal antibody against human Toll - like receplor 3 that blocks double -stranded RNA-mediated signaling[ J]. Biochem Biophys Res Commun, 2002, 293 (5) : 1364-1369. 被引量:1
  • 7LOHMANN V, KOllNER F, KOCH J, et al. Replicalion of Subgenomic Heplilis C Virus RNA in a Hepatoma Cell Line[J]. Science, 1999, 285:110-113. 被引量:1
  • 8LI K, FOY E, FERREON J C, et al. Immune evasion by hepatitis C virus NS3/4A protease - mediated cleavage of the Toll - like receptor3 adaptor protein TRIF [ J ]. Proc Nail Acad Sci U S A, 2005, 102(8) : 2992 - 2997. 被引量:1
  • 9SCHRODFR M, BOWIE A G. TLR3 in antiviral immunity: key player or bystander? [J]. TRENDS Immunol, 2005, 26(9) : 462 - 468. 被引量:1
  • 10UNTERCASSER A, ZEDLER U,LANGENKAMP A. Dendritic cells take up viral antigens but do not support the early steps of hepatitis B virus infection[J]. Hepatology, 2006, 43(3) : 539 - 547. 被引量:1

二级参考文献57

  • 1Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. 42 Dongsi Xidajie,Beijing 100710,China.慢性乙型肝炎防治指南[J].中华肝脏病杂志,2005,13(12):881-891. 被引量:1931
  • 2Qaqish RB,Mattes KA,Ritchie DJ.Adefovir dipivoxil:a new antiviral agent for the treatment of hepatitis B virus infection.Clin Ther,2003,25:3084-3099. 被引量:1
  • 3Hadziyannis S J,Tassopoulos NC,Heathcote E J,et al.Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.N Engl J Med,2005,352:2673-2681. 被引量:1
  • 4Marcellin P,Chang TT,Lim SG,et al.Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.N Engl J Med,2003,348:808-816. 被引量:1
  • 5Kim KM,Choi WB,Lim YS,et al.Adefovir dipivoxil alone or in combination with ongoing lamivudine in patients with decompensated liver disease and lamivudine-resistant hepatitis B virus.J Korean Med Sci,2005,20:821-828. 被引量:1
  • 6Lo CM,Liu CL,Lau GK,et al.Liver transplantation for chronic hepatitis B with lamivudine-resistant YMDD mutant using add-on adefovir dipivoxil plus lamivudine.Liver Transpl,2005,11:807-813. 被引量:1
  • 7Gunther S,Li BC,Miska S,et al.A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients.J Virol,1995,69:5437-5444. 被引量:1
  • 8Gunther S,Sommer G,Von Breunig F,et al.Amplification of full-length hepatitis B virus genomes from samples from patients with low levels of viremia:frequency and functional consequences of PCR-introduced mutations.J Clin Microbiol,1998,36:531-538. 被引量:1
  • 9Khakoo SI,Ling R,Scott I,et al.Cytotoxic T lymphocyte responses and CTL epitope escape mutation in HBsAg,anti-HBe positive individuals.Gut,2000,47:137-143. 被引量:1
  • 10Stuyver LJ,Locarnini SA,Lok A,et al.Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region.Hepatology,2001,33:751-757. 被引量:1

共引文献13

同被引文献37

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部